2009/09/29
Schering Plough (Organon) extends the current research program on nuclear receptors with Shanghai Genomics.
"This program started in 2006 and lasted for more than 3 years. It represents an important starting point for
our research service business. In the future, we will continue to expand outsourcing/service sector," said
Ying Luo, CEO of Shanghai Genomics.
|
2009/09/28 Dr. Ying Luo, Chairman and CEO of Shanghai Genomics, was invited to present the most recent progress of the company's drug development at China Clinical Trials Outsourcing Congress 2009 held in Manchester, United Kingdom.
|
2009/09/10
Dr. Ying Luo, Chairman and CEO of GNI Ltd. and Shanghai Genomics, Inc., was invited to present at the Japan Biotech Forum at London, United Kingdom.
|
2009/08
Dr. Ying Luo, Chairman and CEO of GNI Ltd. and Shanghai Genomics, Inc., received the "Outstanding Innovation and Entrepreneurship Award" at the event of "10th Anniversary of Focus on Zhangjiang".
|
2009/07/14
One of the leading drug candidate for liver fibrosis, F351, has received patent granted by Australia. This is the first step for Shanghai Genomics to seek global protection for F351 in US, Europe, Canada, and Japan. The company has received patent grant in China in 2007. It is currently in Phase I clinical trial in the Peking Union Hospital. At the same time, the company also received patent grant for F647's use in anti-liver fibrosis and anti-acute lung injury. This strenghtened the company's intellectual property position of key products.
|
2009/03/26
Dr. Ying Luo gave a keynote speech at the 2009 & 8th Annual China Pharma, Life Science & Healthcare Industry Summit Week (CPHIS 2009) in Shanghai.
|
2009/02/10
Dr. Ying Luo, Chairman of Shanghai Genomics and CEO of GNI, chaired the IBC Life Sciences Conference: Access India & China. He also presented the drug co-development model of Shanghai Genomics at the conference.
|
2009/01/21
The leading drug candidate F647 demonstrated good results in Phase II trial for Radiation Pneumonitis. In 2008, Shanghai Genomics has completed Phase II trial of F647 for Idiopathic Pulmonary Fibrosis. The Company will prepare for Phase III trial of F647 for Radiation Pneumonitis in the second half of 2009. NDA filing is also be prepared for Idiopathic Pulmonary Fibrosis. Dr. Ying Luo said, "Completion of another Phase II trial of F647 proved that Shanghai Genomics is a leading biotech company in China. With the progress of Phase I trial of F351 for liver fibrosis, Shanghai Genomics will build a rich novel drug pipeline in China."
|
